Pliant Therapeutics, Inc.
PLRX
$1.15
$0.021.32%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -12.86% | 6.45% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 9.60% | 3.30% | |||
| Operating Income | -9.60% | -3.30% | |||
| Income Before Tax | -11.63% | 15.00% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -11.63% | 15.00% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -11.63% | 15.00% | |||
| EBIT | -9.60% | -3.30% | |||
| EBITDA | -9.79% | -3.84% | |||
| EPS Basic | -11.41% | 15.48% | |||
| Normalized Basic EPS | -11.40% | -3.52% | |||
| EPS Diluted | -11.41% | 15.48% | |||
| Normalized Diluted EPS | -11.40% | -3.52% | |||
| Average Basic Shares Outstanding | 0.19% | 0.58% | |||
| Average Diluted Shares Outstanding | 0.19% | 0.58% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||